Effective TB, HIV, malaria vaccines missing from pipeline

Many of the vaccines critically needed to fight the world’s most prevalent infectious diseases are not likely to be developed. A financial modeling study of 538 candidate products for 35 neglected diseases estimated the costs and likelihood that each would progress to a product launch. Using a new tool known as Portfolio-to-Impact (P2I), the researchers found only 128 of those candidates would make it through the drug development pipeline.
Source: Science Daily

Immune discovery should help develop improved vaccines for infants and newborns

Specific immune danger signals are highly efficient in triggering immune responses in infants and newborns, whose immune systems function very differently to those of adults. The scientists believe their discovery could reduce both the age at which vaccines can be first administered, and the need for multiple booster shots.
Source: Science Daily

Immune discovery should help develop improved vaccines for infants and newborns

Specific immune danger signals are highly efficient in triggering immune responses in infants and newborns, whose immune systems function very differently to those of adults. The scientists believe their discovery could reduce both the age at which vaccines can be first administered, and the need for multiple booster shots.
Source: Science Daily